Toggle Main Menu Toggle Search

Open Access padlockePrints

New Therapeutic Horizons for Graves' Hyperthyroidism

Lookup NU author(s): Dr Laura Lane, Professor Timothy Cheetham, Dr Petros Perros, Professor Simon PearceORCiD



This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


© The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society.Graves' hyperthyroidism is characterized by the presence of autoantibodies that stimulate the thyroid-stimulating hormone receptor (TSHR), resulting in uncontrolled secretion of excessive thyroid hormone. Conventional treatments, including antithyroid medication, radioiodine, or surgery have remained largely unchanged for the past 70 years and either lack efficacy for many patients, or result in lifelong thyroid hormone replacement therapy, in the case of the latter 2 options. The demand for new therapeutic options, combined with greater insight into basic immunobiology, has led to the emergence of novel approaches to treat Graves' hyperthyroidism. The current therapies under investigation include biologics, small molecules, and peptide immunomodulation. There is a growing focus on TSHR-specific treatment modalities, which carry the advantage of eliciting a specific, targeted approach, with the aim of avoiding disruption of the functioning immune system. These therapies present a new opportunity to supersede the inadequate treatments currently available for some Graves' patients, offering hope of successful restoration of euthyroidism without the need for ongoing therapy. Several of these therapeutic options have the potential to translate into clinical practice in the near future. This review provides a comprehensive summary of the recent advances and various stages of development of the novel therapeutic approaches to treat Graves' hyperthyroidism.

Publication metadata

Author(s): Lane LC, Cheetham TD, Perros P, Pearce SHS

Publication type: Article

Publication status: Published

Journal: Endocrine Reviews

Year: 2020

Volume: 41

Issue: 6

Print publication date: 01/12/2020

Online publication date: 26/08/2020

Acceptance date: 20/08/2020

Date deposited: 02/11/2020

ISSN (print): 0163-769X

ISSN (electronic): 1945-7189

Publisher: Oxford University Press


DOI: 10.1210/endrev/bnaa022

PubMed id: 32845332


Altmetrics provided by Altmetric


Funder referenceFunder name
MR/S001611/1Medical Research Council (MRC)